Pembrolizumab Combination Shows Robust Antitumor Activity
In 3 phase 1 and 2 studies, improved overall response rates (ORRs) were shown in patients with metastatic melanoma taking pembrolizumab (Keytruda) in combination with 3 other immunotherapies, including epaÂcadostat, talimogene laherparepvec (Imlygic), and ipiÂlimumab (Yervoy). All 3 studies demonstrated significant antitumor activity. In addition, long-term follow-up data in a [ Read More ]